Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The objective of study is to assess the clinical improvement (change in seizure frequency),
safety, and tolerability of subjects with partial seizures following adjunctive therapy of
pregabalin BID (150 to 600 mg/day titration) in addition to existing standards AEDs.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.